medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Número S1

<< Anterior Siguiente >>

Ginecol Obstet Mex 2020; 88 (S1)


Mitos y realidades de la anticoncepción hormonal combinada

Cristóbal-García I, Neyro-Bilbao JL, Carrascoso M

Idioma: Español
Referencias bibliográficas: 51
Paginas: 96-108
Archivo PDF: 255.34 Kb.


RESUMEN

Antecedentes: La anticoncepción ha cambiado el devenir histórico de muchas mujeres, además de permitir su desarrollo personal, sin ligarse a los embarazos sucesivos sin planificación. Hace muchas décadas que la eficacia clínica de la anticoncepción hormonal está fuera de duda, incluso por parte de la población general. Persisten, sin embargo, demasiados mitos acerca de su seguridad y sobre determinadas circunstancias de su empleo que condicionan las decisiones profesionales de la salud y de usuarias potenciales.
Metodología: Ensayo retrospectivo consistente en la búsqueda de artículos originales y revisiones sistemáticas publicados en los últimos diez años en la base de datos de PubMed, específicamente relacionados con temas de anticoncepción hormonal. Las palabras de búsqueda (MeSH) fueron: hormonal contraception, oral contraceptives, myths about oral contraceptives y otros. Se seleccionaron los artículos de mayor nivel de evidencia; se analizaron más de 50 documentos y, de éstos, se ubicaron los más relevantes en cuanto a los mitos y las realidades en torno a la anticoncepción hormonal.
Conclusiones: A pesar del cambio personal y social que la anticoncepción hormonal ha supuesto en los pasados 50 años, persisten aún demasiados mitos acerca de su seguridad y relación con los sangrados regulares, que condicionan negativamente la información proporcionada a las posibles usuarias y las decisiones de la mujer que requiere anticoncepción segura y confortable.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Steptoe PC, et al. Birth after reimplantation of a human embryo. Lancet 1978;2:366.

  2. Pinkus G, et al. Fertility control with oral medication. Am J Obstet Gynecol 1958;75(6):1333-46.

  3. Hauben R. The Internet: On its International Origins and Collaborative Vision. 2004. http://www.ais.org/~jrh/acn/ ACn12-2.a03.txt

  4. Diccionario de la Lengua Española. Edición del Tricentenario. Actualización 2017. http://dle.rae. es/?id=PQM1Wus|PQMf1C3.

  5. Spanish Oxfordliving Dictionaries. https://es.oxforddictionaries.com/definicion/mito.

  6. Neyro JL, et al. Mitos y realidades de los anticonceptivos reversibles de larga duración. Ginecol Obstet Mex 2015;83:707-21.

  7. Encuesta Sociedad Española de Contracepción 2016. http://hosting.sec.es/descargas/OBS_EncuestaAncticoncepcion2016. pdf.

  8. Tolani AT, et al. Many websites fail to dispel myths about IUDs, emergency contraception, birth control and proper timing of pap smears. J Adolescent Health 2009; 44:S24- S25. https://doi.org/10.1016/j.jadohealth.2008.10.056

  9. Ridríguez D, et al. Problematic uses o ICT’s amog young people in their personal and school life. Comunicar 2018;26(5):91-100. https://www.uoc.edu/opencms_portal2/ opencms/ES/in3/publicacions/journal-papers/list.ht ml?groupCode=ALL&mask=&pubSubmit=.

  10. Zolfaroli I, et al. Hormonal contraceptives and breast cancer: Clinical data. Eur J Obstet Gynecol Reprod Biol 2018;230:212-216. https://doi.org/10.1016/j.ejogrb. 2018.03.058.

  11. Anothaisintawee T, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health 2013;25(5):368-87. https://doi. org/10.1177/1010539513488795.

  12. Mørch L, et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. Obstet Gynecol Surv 2018;73(4):215-17.

  13. Mørch LS, et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med 2017;377(23):2228- 39. https://doi.org/10.1056/NEJMoa1700732

  14. American College of Obstetricians and Gynecologists. Practice Advisory: Hormonal Contraception and Risk of Breast Cancer. https://www.acog.org/Clinical-Guidanceand- Publications/Practice-Advisories/Practice-Advisory- Hormonal-Contraception-and-Risk-of-Breast-Cancer.

  15. La Vecchia C, et al. Oral contraceptives, human papillomavirus and cervical cancer. Eur J Cancer Prev 2014;23(2):110- 12. https://doi.org/10.1097/CEJ.0000000000000000.

  16. Bassuk S, et al. Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Ann Epidemiol 2015;25(3):193-200. https://doi.org/10.1016/j. annepidem.2014.11.004.

  17. Vessey MP, et al. Fertility after stopping different methods of contraception. Br Med J 1978;1(6108):265-7.

  18. Hassan MA, et al. Is previous use of hormonal contraception associated with a detrimental effect on subsequent fecundity? Hum Reprod 2004;19(2):344-51.

  19. Kaplan B, et al. Use of various contraceptive methods and time of conception in a community-based population. Eur J Obstet Gynecol Reprod Biol 2005;123(1):72-6. https://doi. org/10.1016/j.ejogrb.2005.06.033

  20. Axmon A, et al. Factors affecting time to pregnancy. Hum Reprod 2006;21(5):1279-84. https://doi.org/10.1093/ humrep/dei469

  21. Wiegratz I, et al. Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of dienogest. Fertil Steril 2006;85(6):1812-9. https://doi.org/10.1016/j.fertnstert.2005.11.052

  22. Cronin M, et al. Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives. Obstet Gynecol 2009;114(3):616-22. https://doi.org/10.1097/ AOG.0b013e3181b46f54.

  23. Barnhart KT, et al. Return to fertility following discontinuation of oral contraceptives. Fertil Steril 2009;91(3):659-63. https://doi.org/10.1016/j.fertnstert.2009.01.003.

  24. Mikkelsen E, et al. Pre-gravid oral contraceptive use and time to pregnancy: a Danish prospective cohort study. Hum Reprod 2013;28(5):1398-405. https://doi.org/10.1093/ humrep/det023.

  25. Farrow A, et al. Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception. Hum Reprod 2002;17(11):3009-10.

  26. Gallo MF, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2014;29;1:CD003987. https://doi.org/10.1002/14651858.CD003987.pub5.

  27. Rosenberg MJ, et al. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995;51(5):283-8.

  28. Emans SJ, et al. Adolescents' compliance with the use of oral contraceptives. JAMA 1987;257(24):3377-81.

  29. Mayeda E, et al. Weight and body composition changes during oral contraceptive use in obese and normal weight women. J Womens Health (Larchmt) 2014;23(1):38-43. https://doi.org/10.1089/jwh.2012.4241.

  30. Lindh I, et al. The long-term influence of combined oral contraceptives on body weight. Hum Reprod 2011;26(7):1917- 24. https://doi.org/10.1093/humrep/der094.

  31. Organización Mundial de la Salud OMS. Recomendaciones sobre prácticas seleccionadas para el uso de anticonceptivos, tercera edición [Selected practice recommendations for contraceptive use, 3rd edition] ISBN 978-92-4-356540-8. 2018

  32. Chabbert-Buffet N, et al. Missed pills: frequency, reasons, consequences and solutions. Eur J Contracept Reprod Health Care 2017;22(3):165-69. https://doi.org/10.1080 /13625187.2017.1295437.

  33. Sitruk-Wae R. Hormonal contraception and thrombosis. Fertil Steril. 2016;106(6):1289-94. https://doi. org/10.1016/j.fertnstert.2016.08.039.

  34. Letourneau J, et al. Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield. J Assist Reprod Genet 2017;34(9):1137- 44. https://doi.org/10.1007/s10815-017-0981-8.

  35. Cooper D, et al. Oral Contraceptive Pills. https://www.ncbi. nlm.nih.gov/books/NBK430882/.

  36. Turner J. Current barriers and potential strategies to increase the use of long-acting reversible contraception to reduce the rate of unintended pregnancies in Australia: An expert roundtable discussion. Aust N Z J Obstet Gynaecol 2017;57(6):206-12. https://doi.org/10.1111/ajo.12587.

  37. Vandever MA, et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception. 2008;77(3):162-70. https://doi.org/10.1016/j. contraception.2007.11.005.

  38. Levítico 15:19-33. https://www.biblestudytools.com/bla/ levitico/passage/?q=levitico+15:19-33.

  39. Gayo Plinio Segundo. Historia Natural, libro 28, 23, 78-80.

  40. Julius Rufinus Von Bologna, Summa Decretorum, passim. Accesible en https://www.theologie.uni-wuerzburg.de/ fileadmin/01040030/Rufin_Singer_fulltext.pdf.

  41. Thomas SL, et al. Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet 2000;355(9207):922-24. https://doi.org/10.1016/S0140- 6736(99)11159-0

  42. Miller L, et al. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003;101(4):653-61.

  43. Sulak PJ, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95(2):261-66.

  44. Willis SA, et al. Greater inhibition of the pituitary--ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006;74(2):100-3. https://doi.org/10.1016/j.contraception.2006.02.006

  45. Edelman A, et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev 2014;29(7):CD004695. https://doi.org/10.1002/14651858.CD004695.pub3.

  46. Wiegratz I, et al. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception 2011;84(2):133-43. https://doi.org/10.1016/j.contraception. 2011.01.002.

  47. Vercellini P, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003;80:560-63.

  48. Davis AR, et al. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril 2008;89(5):1059-63. https://doi.org/10.1016/j.fertnstert. 2007.05.012

  49. Wiegratz I, et al. Effects of conventional or extendedcycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception 2008;785:384-91. https://doi. org/10.1016/j.contraception.2008.06.015.

  50. Machado RB, et al. Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles. Contraception 2010;81(2):102-6. https://doi.org/10.1016/j. contraception.2009.08.009.

  51. Neyro JL, Elorriaga MA, Cristóbal I, et al. Comentario del experto en anticoncepción. Barcelona: Ediciones Médicas. www.euromedice.net.




2020     |     www.medigraphic.com